Base-edited hematopoietic stem and progenitor cells + ALEMTUZUMAB + Busulfan + FILGRASTIM + PALIFERMIN + PLERIXAFOR for x-linked combined immunodeficiency diseases

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 28 Feb 2025: Trial registered, NCT06851767
  2. 9 May 2025: Trial started, NCT06851767

The trials

NCT06851767: Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

State
Under way
Phase
Phase 1 and Phase 2
People
18 planned
Started
9 May 2025
Primary completion
31 Dec 2034
Arms
Single Arm Study
Results
None posted
  1. 28 Feb 2025: Trial registered
  2. 9 May 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.